Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]
, 2010 Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Al Saeidi, Rashid +6 more
core +1 more source
Indicators of Visual Prognosis in Diabetic Macular Oedema [PDF]
Journal of Personalized Medicine, 2021 Diabetic macular oedema (DMO) is an important cause of moderate vision loss in people with diabetes. Advances in imaging technology have shown that a significant proportion of patients with DMO respond sub-optimally to existing treatment options. Identifying associations and predictors of response before treatment is initiated may help in explaining ...
Sagnik Sen +2 more
openaire +2 more sources
Diagnosing and monitoring diabetic macular edema: structural and functional tests. [PDF]
, 2015 Diabetic macular edema remains a major cause of visual impairment in adults despite the use of intensive glycemic control, photocoagulation therapy and new intravitreal drugs in the treatment of this disease.
Midena, Edoardo, Vujosevic, Stela
core +1 more source
Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery. [PDF]
, 2016 BACKGROUND: Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision ...
Bunce, Catey +5 more
core +2 more sources
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment : evidence from the RESTORE trial [PDF]
, 2012 Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare ...
Annemans, Lieven +7 more
core +3 more sources
Intravitreal Ranibizumab for Diabetic Macular Oedema [PDF]
European Ophthalmic Review, 2015 Diabetic macular oedema (DMO) is the most frequent cause of vision loss in patients affected by diabetes mellitus, and has a remarkable effect on public health. The treatment with focal/grid laser photocoagulation was considered in the past decades as the standard of care, but the recent advent of new pharmacological approaches, based on the use of ...
Maurizio Battaglia Parodi +2 more
openaire +1 more source
Evaluation of Visual Outcomes of Cataract Surgery in Diabetic Patients and Assessment of Post-operative Complications as Compared to Non-diabetics [PDF]
Journal of Clinical and Diagnostic Research, 2019 Introduction: A leading cause of vision loss in the young adult population worldwide is sequelae and complications of diabetes. Cataract surgery performed on diabetic patients accounts for approximately 20% of total cataract surgeries.
Neha Singh, Shobha G Pai, Tina Anne John
doaj +1 more source
Diabetic retinopathy screening: global and local perspective [PDF]
, 2016 Diabetes mellitus has become a global epidemic. It causes significant macrovascular complications such as coronary artery disease, peripheral artery disease, and stroke; as well as microvascular complications such as retinopathy, nephropathy, and ...
Gangwani, RA +4 more
core +1 more source
Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities [PDF]
, 2017 To assess specific morphologic and functional characteristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND+) vs DME without SND (SND-)
Berton, Marianna +5 more
core +1 more source
HbA1c as a predictor for response of bevacizumab in diabetic macular oedema
BMJ Open Ophthalmology, 2020 Objective To study the influence of glycosylated haemoglobin (HbA1c) on response of bevacizumab in patients with diabetic macular oedema.Methods and Analysis A total of 37 eyes of 37 patients with vision loss due to diabetic macular oedema treated with ...
Sadhana Sharma +2 more
doaj +1 more source